Galectin Therapeutics Files 8-K

Ticker: GALT · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1133416

Galectin Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyGalectin Therapeutics INC (GALT)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, financials, regulation-fd

Related Tickers: GALT

TL;DR

GALECTIN THERAPEUTICS (GALT) filed an 8-K on Jan 13, 2025, reporting financials and exhibits.

AI Summary

Galectin Therapeutics Inc. filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Pro Pharmaceuticals Inc., is incorporated in Nevada and headquartered in Norcross, Georgia.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and potential disclosures relevant to investors.

Risk Assessment

Risk Level: low — This is a standard 8-K filing for corporate reporting and does not appear to contain material non-public information that would immediately impact stock price.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting a Regulation FD Disclosure and Financial Statements and Exhibits.

When was this report filed?

The report was filed on January 13, 2025.

What is the company's principal executive office address?

The company's principal executive office is located at 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071.

What was the company's former name?

The company's former name was PRO PHARMACEUTICALS INC.

In which state is Galectin Therapeutics Inc. incorporated?

Galectin Therapeutics Inc. is incorporated in Nevada.

Filing Stats: 621 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-13 08:00:29

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 13, 2025, Galectin Therapeutics Inc. (the "Company") is making its updated corporate presentation available on its website. The Company intends to use the presentation at conferences and meetings with investors, shareholders and analysts. A copy of the presentation is furnished herewith as Exhibit 99.1 and incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information furnished under this Item 7.01 of this Current Report on Form 8-K and the exhibits attached hereto are deemed to be "furnished" and shall not be deemed "filed" for the purpose of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information and exhibits be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended. This Current Report on Form 8-K and Exhibit 99.1 hereto contain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit Description 99.1 Galectin Therapeutic Inc. Corporate Presentation, updated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Galectin Therapeutics Inc. Date: January 13, 2025 By: /s/ Jack W. Callicutt Jack W. Callicutt Chief Financial Officer - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing